Wall Street brokerages predict that Ascendis Pharma A/S (NASDAQ:ASND) will post sales of $570,000.00 for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Ascendis Pharma A/S’s earnings, with the highest sales estimate coming in at $1.16 million and the lowest estimate coming in at $50,000.00. Ascendis Pharma A/S posted sales of $1.13 million during the same quarter last year, which would indicate a negative year over year growth rate of 49.6%. The business is scheduled to announce its next quarterly earnings report on Wednesday, March 28th.

According to Zacks, analysts expect that Ascendis Pharma A/S will report full-year sales of $570,000.00 for the current year, with estimates ranging from $1.97 million to $2.00 million. For the next year, analysts expect that the firm will report sales of $2.52 million per share, with estimates ranging from $940,000.00 to $5.00 million. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Ascendis Pharma A/S.

Several equities analysts have commented on the stock. Wells Fargo & Company restated a “buy” rating and issued a $51.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, September 22nd. Wedbush restated an “outperform” rating and issued a $10.71 price objective (down previously from $65.00) on shares of Ascendis Pharma A/S in a research note on Friday, September 22nd. Credit Suisse Group restated an “outperform” rating and issued a $50.00 price objective (up previously from $30.00) on shares of Ascendis Pharma A/S in a research note on Friday, September 22nd. Zacks Investment Research cut shares of Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a report on Wednesday, August 23rd. Finally, Leerink Swann restated a “hold” rating and set a $28.00 target price on shares of Ascendis Pharma A/S in a research report on Friday, September 1st. Two analysts have rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $36.45.

A number of large investors have recently added to or reduced their stakes in ASND. Bank of Montreal Can increased its holdings in Ascendis Pharma A/S by 127.4% in the 2nd quarter. Bank of Montreal Can now owns 4,535 shares of the biotechnology company’s stock valued at $126,000 after buying an additional 2,541 shares during the period. Bank of America Corp DE grew its holdings in Ascendis Pharma A/S by 23.6% during the 1st quarter. Bank of America Corp DE now owns 5,345 shares of the biotechnology company’s stock worth $150,000 after acquiring an additional 1,020 shares during the last quarter. Victory Capital Management Inc. bought a new stake in Ascendis Pharma A/S during the 3rd quarter worth about $194,000. Deschutes Portfolio Strategy LLC bought a new stake in Ascendis Pharma A/S during the 2nd quarter worth about $238,000. Finally, Aperio Group LLC bought a new stake in Ascendis Pharma A/S during the 3rd quarter worth about $241,000. Hedge funds and other institutional investors own 78.93% of the company’s stock.

Shares of Ascendis Pharma A/S (NASDAQ:ASND) opened at $36.47 on Thursday. Ascendis Pharma A/S has a 12-month low of $19.21 and a 12-month high of $42.00.

COPYRIGHT VIOLATION WARNING: This news story was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/12/07/ascendis-pharma-as-asnd-expected-to-post-quarterly-sales-of-570000-00.html.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Get a free copy of the Zacks research report on Ascendis Pharma A/S (ASND)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.